These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 27535079)

  • 1. Pharmacist Screening for Risk of Osteoporosis in Elderly Veterans.
    Salvig BE; Gulum AH; Walters SA; Edwards LB; Fourakre TN; Marvin SC; McKenzie MS; Moseley MV; Ansari IJ
    Consult Pharm; 2016; 31(8):440-9. PubMed ID: 27535079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact on the population of different bone mineral density testing criteria and appropriateness of densitometries in the ESOSVAL cohort, Spain.
    Hurtado I; Sanfélix-Gimeno G; Baixauli-Pérez C; Peiró S; Sanfélix-Genovés J
    J Clin Endocrinol Metab; 2014 Jan; 99(1):142-50. PubMed ID: 24384018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic.
    Stroup JS; Rivers SM; Abu-Baker AM; Kane MP
    Pharmacotherapy; 2007 Jun; 27(6):779-88. PubMed ID: 17542760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone mineral density screening and its accordance with Canadian clinical practice guidelines from 2000-2013: an unchanging landscape in Saskatchewan, Canada.
    McLeod KM; Johnson S; Charturvedi R; St Onge J; Lionel A; Verma A
    Arch Osteoporos; 2015; 10():227. PubMed ID: 26173601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Community pharmacist-initiated screening program for osteoporosis: randomized controlled trial.
    Yuksel N; Majumdar SR; Biggs C; Tsuyuki RT
    Osteoporos Int; 2010 Mar; 21(3):391-8. PubMed ID: 19499272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence of academic geriatric practitioners to osteoporosis screening guidelines.
    McNally DN; Kenny AM; Smith JA
    Osteoporos Int; 2007 Feb; 18(2):177-83. PubMed ID: 17043904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FRAX without bone mineral density versus osteoporosis self-assessment screening tool as predictors of osteoporosis in primary screening of individuals aged 70 and older.
    Pang WY; Inderjeeth CA
    J Am Geriatr Soc; 2014 Mar; 62(3):442-6. PubMed ID: 24617899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving osteoporosis screening, risk assessment, diagnosis, and treatment initiation: role of the health-system pharmacist in closing the gap.
    MacLaughlin EJ
    Am J Health Syst Pharm; 2010 Apr; 67(7 Suppl 3):S4-8. PubMed ID: 20332497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age at First Osteoporosis Screening Among Older Women and Men: Is Bone Mineral Density Measurement Ordered Timely?
    Tasci I; Basgoz BB; Cintosun U; Safer U; Naharci MI
    Endocr Metab Immune Disord Drug Targets; 2019; 19(4):534-540. PubMed ID: 30585552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of bone mineral density testing in patients at high risk of osteoporosis: secondary analyses from the OSTEOPHARM randomized trial.
    Yuksel N; Tsuyuki RT; Majumdar SR
    J Clin Densitom; 2012; 15(1):61-6. PubMed ID: 22071024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice.
    Lim LS; Hoeksema LJ; Sherin K;
    Am J Prev Med; 2009 Apr; 36(4):366-75. PubMed ID: 19285200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of FRAX as a determinant for risk-based osteoporosis screening may decrease unnecessary testing while improving the odds of identifying treatment candidates.
    Edwards FD; Grover ML; Cook CB; Chang YH
    Womens Health Issues; 2014; 24(6):629-34. PubMed ID: 25128036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for osteoporosis: recommendation statement.
    U.S. Preventive Services Task Force
    Am Fam Physician; 2011 May; 83(10):1197-200. PubMed ID: 21568254
    [No Abstract]   [Full Text] [Related]  

  • 14. Addition of a fracture risk assessment to a coordinator's role improved treatment rates within 6 months of screening in a fragility fracture screening program.
    Beaton DE; Vidmar M; Pitzul KB; Sujic R; Rotondi NK; Bogoch ER; Sale JEM; Jain R; Weldon J
    Osteoporos Int; 2017 Mar; 28(3):863-869. PubMed ID: 27770155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective evaluation of medication appropriateness and clinical pharmacist drug therapy recommendations for home-based primary care veterans.
    Davis RG; Hepfinger CA; Sauer KA; Wilhardt MS
    Am J Geriatr Pharmacother; 2007 Mar; 5(1):40-7. PubMed ID: 17608246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoporosis screening and education in community pharmacies using a team approach.
    MacLaughlin EJ; MacLaughlin AA; Snella KA; Winston TS; Fike DS; Raehl CR
    Pharmacotherapy; 2005 Mar; 25(3):379-86. PubMed ID: 15843285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation and adherence to osteoporosis screening guidelines among coeliac disease patients.
    Singh P; Garber JJ
    Dig Liver Dis; 2016 Dec; 48(12):1451-1456. PubMed ID: 27665261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoporosis screening for men: are family physicians following the guidelines?
    Cheng N; Green ME
    Can Fam Physician; 2008 Aug; 54(8):1140-1141, 1141.e1-5. PubMed ID: 18697977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for osteoporosis.
    Croswell J
    Am Fam Physician; 2011 May; 83(10):1201-2. PubMed ID: 21568255
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of pharmacist-led community bone mineral density screenings.
    Summers KM; Brock TP
    Ann Pharmacother; 2005 Feb; 39(2):243-8. PubMed ID: 15613465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.